Coverage evaluation of mass drug administration for lymphatic filariasis in four endemic districts of Jharkhand, India

Lymphatic filariasis (LF) remains endemic in several districts of Jharkhand despite repeated Mass Drug Administration (MDA) rounds. This study assessed drug coverage, compliance, and associated factors in four endemic districts: Deoghar, Dumka, Giridih, and Godda. A community-based cross-sectional Coverage Evaluation Survey (CES) was conducted within six weeks of MDA. The double-drug regimen (Diethylcarbamazine and Albendazole) (DA) was administered in Deoghar and Giridih, and the triple-drug regimen (Ivermectin, Diethylcarbamazine, and Albendazole) (IDA) in Dumka and Godda. Using multistage random sampling of clusters and systematic selection of adjacent households within each cluster, 2,400 households (14,782 individuals) were surveyed. Coverage indicators were calculated per World Health Organization (WHO) guidelines. Overall drug coverage was 52.1%, and epidemiological drug coverage was 49.2%. Complete household-level MDA drug coverage was 45.0%, highest in Dumka (58.2%) and lowest in Giridih (28.8%). In multivariable logistic regression analysis, significant predictors of complete household-level MDA drug coverage included higher educational level (adjusted odds ratio [aOR]: 1.05), residence in Dumka (aOR: 1.63) or Godda (aOR: 1.40), tribal (aOR: 2.27) or rural area (aOR: 2.02), awareness of LF (aOR: 1.87), knowledge that LF is mosquito-borne (aOR: 1.32), prior MDA communication (aOR: 2.64), and participation in two or more previous MDA rounds (aOR: 2.30). Larger household size was negatively associated (aOR: 0.88). Among MDA participants, adverse events were significantly more common when drugs were consumed on an empty stomach (p < 0.001). None of the districts achieved WHO-recommended epidemiological coverage thresholds (≥ 65% for DA and ≥ 85% for IDA). Strengthening community engagement and pre-campaign communication is essential for improving MDA outcomes and accelerating LF elimination.

Authors

Institutions

Publication Details

Journal
Journal of Health Population and Nutrition
Published
2025-12-08
DOI
https://doi.org/10.1186/s41043-025-01185-7
Primary Topic
Parasitic Diseases Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Coverage evaluation of mass drug administration for lymphatic filariasis in four endemic districts of Jharkhand, India

G Jahnavi, Pratima Gupta, Abhishek Paul, Saurabh Varshney et al.
Journal of Health Population and Nutrition
Parasitic Diseases Research and Treatment
article

Coverage evaluation of mass drug administration for lymphatic filariasis in four endemic districts of Jharkhand, India

G Jahnavi, Pratima Gupta, Abhishek Paul, Saurabh Varshney, Bijit Biswas
article en

Abstract

Lymphatic filariasis (LF) remains endemic in several districts of Jharkhand despite repeated Mass Drug Administration (MDA) rounds. This study assessed drug coverage, compliance, and associated factors in four endemic districts: Deoghar, Dumka, Giridih, and Godda. A community-based cross-sectional Coverage Evaluation Survey (CES) was conducted within six weeks of MDA. The double-drug regimen (Diethylcarbamazine and Albendazole) (DA) was administered in Deoghar and Giridih, and the triple-drug regimen (Ivermectin, Diethylcarbamazine, and Albendazole) (IDA) in Dumka and Godda. Using multistage random sampling of clusters and systematic selection of adjacent households within each cluster, 2,400 households (14,782 individuals) were surveyed. Coverage indicators were calculated per World Health Organization (WHO) guidelines. Overall drug coverage was 52.1%, and epidemiological drug coverage was 49.2%. Complete household-level MDA drug coverage was 45.0%, highest in Dumka (58.2%) and lowest in Giridih (28.8%). In multivariable logistic regression analysis, significant predictors of complete household-level MDA drug coverage included higher educational level (adjusted odds ratio [aOR]: 1.05), residence in Dumka (aOR: 1.63) or Godda (aOR: 1.40), tribal (aOR: 2.27) or rural area (aOR: 2.02), awareness of LF (aOR: 1.87), knowledge that LF is mosquito-borne (aOR: 1.32), prior MDA communication (aOR: 2.64), and participation in two or more previous MDA rounds (aOR: 2.30). Larger household size was negatively associated (aOR: 0.88). Among MDA participants, adverse events were significantly more common when drugs were consumed on an empty stomach (p < 0.001). None of the districts achieved WHO-recommended epidemiological coverage thresholds (≥ 65% for DA and ≥ 85% for IDA). Strengthening community engagement and pre-campaign communication is essential for improving MDA outcomes and accelerating LF elimination.

Journal of Health Population and NutritionVol. 45(1)
World Health Organization - India (IN), All India Institute of Medical Sciences, Deoghar (IN)
Openalex Percentile: Top 55%
Parasitic Diseases Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.